Posted on

cbd dosage for brain tumor

1:1 ratio with an ethanol excipient. Similar preclinical anti-tumour effects were also seen in GBM cells with a ‘Sativex-like’ formulation, including significant xenograft growth inhibition in combination with temozolomide. 7 This was also seen using the relatively temozolomide-resistant GBM cell line T98G, where a combination of temozolomide and THC or a ‘Sativex-like’ formulation led to significant tumour growth inhibition (unobserved with any of these alone). Consistent findings were later observed from similar experiments using oral cannabinoid administration, while such synergy was not observed between these compounds and lomustine chemotherapy (which is commonly used in recurrent GBM). 9 These data, and other supporting findings, led to the hypotheses that THC or THC/CBD combinations (including Sativex®) in combination with temozolomide may have potential clinical utility in patients with GBM. A pilot study of intracranial THC administration directly into the surgical cavity of nine patients with recurrent, resected GBM showed a reduction in tumour cell proliferation in the two patients who had further biopsies on the study. 6 While this approach appeared tolerable, outcomes in this study remained poor. Anecdotal reports and case series suggesting anti-cancer efficacy of cannabinoid preparations in patients with GBM 10 are limited by possible selection bias, other concomitant or recent treatments with proven efficacy, and potential issues with pseudo-progression after such treatments.

Change history

Regardless of any potential differences between arms in Part 2, the overall survival in this trial population remains impressive, although it is difficult to conceive how this may be modulated by either nabiximols or DIT given the absence of a signal for improvement in PFS. Nevertheless, these interesting findings, backed up by a strong preclinical rationale, still warrant urgent exploration of the combination of temozolomide and nabiximols in a sufficiently powered larger study. A Phase 1b study (GEINOCANN; NCT03529448) will study TN-TC11G in combination with radiotherapy and temozolomide in first-line treatment of GBM (with a recruitment target of 30 patients). It is crucial that clinical research efforts are combined with solid translational research to attempt to identify any potential predictive biomarkers for cannabinoid efficacy.


Twelves, C., Sabel, M., Checketts, D., Miller, S., Tayo, B., Jove, M. et al. A Phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br. J. Cancer (2021).

Cbd dosage for brain tumor

The researchers believe that CBD’s anti-cancer actions target mitochondria — the cell’s energy producing structures — by causing the mitochondria to dysfunction and release harmful reactive oxygen species. The mitochondria (teal color) in a canine cancer cell line are shown after 48 hours of treatment with a nonlethal dose of CBD isolate (40x objective lens). Credit: Chase Gross, Mando Ramirez, Jade Kurihara, Colorado State University

The researchers believe that CBD’s anti-cancer actions target mitochondria—the cell’s energy producing structures—by causing the mitochondria to dysfunction and release harmful reactive oxygen species. Their experiments showed that cells treated with CBD exhibited significant decreases in mitochondrial activity.

Mr. Gross was scheduled to present this research at the American Society for Pharmacology and Experimental Therapeutics annual meeting in San Diego this month. Though the meeting, to be held in conjunction with the 2020 Experimental Biology conference, was canceled in response to the COVID-19 outbreak, the research team’s abstract was published in this month’s issue of The FASEB Journal.